Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Role of IL-35 in sublingual allergen immunotherapy.

Shamji MH, Layhadi JA, Achkova D, Kouser L, Perera-Webb A, Couto-Francisco NC, Parkin RV, Matsuoka T, Scadding G, Ashton-Rickardt PG, Durham SR.

J Allergy Clin Immunol. 2019 Mar;143(3):1131-1142.e4. doi: 10.1016/j.jaci.2018.06.041. Epub 2018 Jul 25.

2.

C1q restrains autoimmunity and viral infection by regulating CD8+ T cell metabolism.

Ling GS, Crawford G, Buang N, Bartok I, Tian K, Thielens NM, Bally I, Harker JA, Ashton-Rickardt PG, Rutschmann S, Strid J, Botto M.

Science. 2018 May 4;360(6388):558-563. doi: 10.1126/science.aao4555.

3.

T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations.

Ghosh S, Carmo M, Calero-Garcia M, Ricciardelli I, Bustamante Ogando JC, Blundell MP, Schambach A, Ashton-Rickardt PG, Booth C, Ehl S, Lehmberg K, Thrasher AJ, Gaspar HB.

J Allergy Clin Immunol. 2018 Sep;142(3):904-913.e3. doi: 10.1016/j.jaci.2017.11.050. Epub 2018 Jan 31.

4.

Antiapoptotic serine protease inhibitors contribute to survival of allergenic TH2 cells.

Shamji MH, Temblay JN, Cheng W, Byrne SM, Macfarlane E, Switzer AR, Francisco NDC, Olexandra F, Jacubczik F, Durham SR, Ashton-Rickardt PG.

J Allergy Clin Immunol. 2018 Aug;142(2):569-581.e5. doi: 10.1016/j.jaci.2017.07.055. Epub 2017 Oct 26.

5.

Mitochondria Apply the Brake to Viral Immunity.

Ashton-Rickardt PG.

Cell Metab. 2016 Jun 14;23(6):967-968. doi: 10.1016/j.cmet.2016.05.018.

6.

T cell metabolism. The protein LEM promotes CD8⁺ T cell immunity through effects on mitochondrial respiration.

Okoye I, Wang L, Pallmer K, Richter K, Ichimura T, Haas R, Crouse J, Choi O, Heathcote D, Lovo E, Mauro C, Abdi R, Oxenius A, Rutschmann S, Ashton-Rickardt PG.

Science. 2015 May 29;348(6238):995-1001. doi: 10.1126/science.aaa7516. Epub 2015 Apr 16. Erratum in: Science. 2015 Oct 23;350(6259):aad6462. Retraction in: Science. 2016 Dec 16;354(6318):1385.

7.

A memory of rejection?

Ashton-Rickardt PG.

Am J Transplant. 2015 Jan;15(1):13-4. No abstract available.

8.

Approaches to design non-covalent inhibitors for human granzyme B (hGrB).

Kim MS, Buisson LA, Heathcote DA, Hu H, Braddock DC, Barrett AG, Ashton-Rickardt PG, Snyder JP.

Org Biomol Chem. 2014 Nov 28;12(44):8952-65. doi: 10.1039/c4ob01874e.

PMID:
25277547
9.

Brief report: serpin Spi2A as a novel modulator of hematopoietic progenitor cell formation.

Li L, Byrne SM, Rainville N, Su S, Jachimowicz E, Aucher A, Davis DM, Ashton-Rickardt PG, Wojchowski DM.

Stem Cells. 2014 Sep;32(9):2550-6. doi: 10.1002/stem.1778.

10.
11.

Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells.

Azzi J, Skartsis N, Mounayar M, Magee CN, Batal I, Ting C, Moore R, Riella LV, Ohori S, Abdoli R, Smith B, Fiorina P, Heathcote D, Bakhos T, Ashton-Rickardt PG, Abdi R.

J Immunol. 2013 Sep 1;191(5):2319-27. doi: 10.4049/jimmunol.1300851. Epub 2013 Aug 2.

12.

An emerging role for Serine Protease Inhibitors in T lymphocyte immunity and beyond.

Ashton-Rickardt PG.

Immunol Lett. 2013 Apr;152(1):65-76. doi: 10.1016/j.imlet.2013.04.004. Epub 2013 Apr 25. Review.

PMID:
23624075
13.

Delivery of a granzyme B inhibitor gene using carbamate-mannose modified PEI protects against cytotoxic lymphocyte killing.

Cheng W, Yang C, Hedrick JL, Williams DF, Yang YY, Ashton-Rickardt PG.

Biomaterials. 2013 May;34(14):3697-705. doi: 10.1016/j.biomaterials.2013.01.090. Epub 2013 Feb 16.

PMID:
23422590
14.

Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins.

Dev A, Byrne SM, Verma R, Ashton-Rickardt PG, Wojchowski DM.

J Exp Med. 2013 Feb 11;210(2):225-32. doi: 10.1084/jem.20121762. Epub 2013 Jan 14. Erratum in: J Exp Med. 2014 Feb 10;211(2):381.

15.

Cathepsin B controls the persistence of memory CD8+ T lymphocytes.

Byrne SM, Aucher A, Alyahya S, Elder M, Olson ST, Davis DM, Ashton-Rickardt PG.

J Immunol. 2012 Aug 1;189(3):1133-43. doi: 10.4049/jimmunol.1003406. Epub 2012 Jun 27.

16.

A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival.

Choi O, Heathcote DA, Ho KK, Müller PJ, Ghani H, Lam EW, Ashton-Rickardt PG, Rutschmann S.

J Immunol. 2012 Apr 15;188(8):3920-7. doi: 10.4049/jimmunol.1102587. Epub 2012 Mar 9.

17.

Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death.

Lovo E, Zhang M, Wang L, Ashton-Rickardt PG.

J Immunol. 2012 Feb 1;188(3):1057-63. doi: 10.4049/jimmunol.1102667. Epub 2012 Jan 6.

18.

The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells.

El Haddad N, Moore R, Heathcote D, Mounayar M, Azzi J, Mfarrej B, Batal I, Ting C, Atkinson M, Sayegh MH, Ashton-Rickardt PG, Abdi R.

J Immunol. 2011 Sep 1;187(5):2252-60. doi: 10.4049/jimmunol.1003981. Epub 2011 Jul 27.

19.

Mesenchymal stem cells express serine protease inhibitor to evade the host immune response.

El Haddad N, Heathcote D, Moore R, Yang S, Azzi J, Mfarrej B, Atkinson M, Sayegh MH, Lee JS, Ashton-Rickardt PG, Abdi R.

Blood. 2011 Jan 27;117(4):1176-83. doi: 10.1182/blood-2010-06-287979. Epub 2010 Nov 12.

20.

Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage.

Ansari AW, Temblay JN, Alyahya SH, Ashton-Rickardt PG.

J Immunol. 2010 Jul 15;185(2):877-83. doi: 10.4049/jimmunol.1000651. Epub 2010 Jun 11.

21.

Serine protease inhibitors and cytotoxic T lymphocytes.

Ashton-Rickardt PG.

Immunol Rev. 2010 May;235(1):147-58. doi: 10.1111/j.0105-2896.2010.00892.x. Review.

PMID:
20536561
22.

CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia.

Park SM, Rajapaksha TW, Zhang M, Sattar HA, Fichera A, Ashton-Rickardt PG, Peter ME.

Apoptosis. 2008 Jan;13(1):41-51.

PMID:
17955374
23.

Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa.

Zhang M, Liu N, Park SM, Wang Y, Byrne S, Murmann AE, Bahr S, Peter ME, Olson ST, Belaaouaj A, Ashton-Rickardt PG.

J Immunol. 2007 Oct 1;179(7):4390-6.

24.

Studying T-cell repertoire selection using fetal thymus organ culture.

Ashton-Rickardt PG.

Methods Mol Biol. 2007;380:171-84. Review.

PMID:
17876093
25.

Differential survival of cytotoxic T cells and memory cell precursors.

Zhang M, Byrne S, Liu N, Wang Y, Oxenius A, Ashton-Rickardt PG.

J Immunol. 2007 Mar 15;178(6):3483-91.

26.

Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules.

Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, Wang CR, Peter ME, Ashton-Rickardt PG.

Immunity. 2006 Apr;24(4):451-61.

27.

The granule pathway of programmed cell death.

Ashton-Rickardt PG.

Crit Rev Immunol. 2005;25(3):161-82. Review.

PMID:
16048434
28.

A license to remember.

Ashton-Rickardt PG.

Nat Immunol. 2004 Nov;5(11):1097-8. No abstract available.

PMID:
15496944
29.

A role for the granzyme B inhibitor serine protease inhibitor 6 in CD8+ memory cell homeostasis.

Phillips T, Opferman JT, Shah R, Liu N, Froelich CJ, Ashton-Rickardt PG.

J Immunol. 2004 Sep 15;173(6):3801-9.

30.

Serine protease inhibitor 2A is a protective factor for memory T cell development.

Liu N, Phillips T, Zhang M, Wang Y, Opferman JT, Shah R, Ashton-Rickardt PG.

Nat Immunol. 2004 Sep;5(9):919-26. Epub 2004 Aug 15.

PMID:
15311278
31.

Serine protease inhibitor 2A inhibits caspase-independent cell death.

Liu N, Wang Y, Ashton-Rickardt PG.

FEBS Lett. 2004 Jul 2;569(1-3):49-53.

32.

NF-kappaB protects from the lysosomal pathway of cell death.

Liu N, Raja SM, Zazzeroni F, Metkar SS, Shah R, Zhang M, Wang Y, Brömme D, Russin WA, Lee JC, Peter ME, Froelich CJ, Franzoso G, Ashton-Rickardt PG.

EMBO J. 2003 Oct 1;22(19):5313-22.

33.

A critical role for NF-kappaB transcription factors in the development of CD8+ memory-phenotype T cells.

Hettmann T, Opferman JT, Leiden JM, Ashton-Rickardt PG.

Immunol Lett. 2003 Feb 3;85(3):297-300.

PMID:
12663146
34.
35.

Suicide induced by cytolytic activity controls the differentiation of memory CD8(+) T lymphocytes.

Opferman JT, Ober BT, Narayanan R, Ashton-Rickardt PG.

Int Immunol. 2001 Apr;13(4):411-9.

PMID:
11282980
36.

What keeps a resting T cell alive?

Thompson CB, Rathmell JC, Frauwirth KA, Lindsten T, Rudin CM, Opferman JT, Ashton-Rickardt PG, Harris MH, Chandel NS, Schumacker PT, Vander Heiden MG.

Cold Spring Harb Symp Quant Biol. 1999;64:383-7. Review. No abstract available.

PMID:
11232311
37.

Affinity of thymic self-peptides for the TCR determines the selection of CD8(+) T lymphocytes in the thymus.

Ober BT, Hu Q, Opferman JT, Hagevik S, Chiu N, Wang CR, Ashton-Rickardt PG.

Int Immunol. 2000 Sep;12(9):1353-63.

PMID:
10967031
38.

Linear differentiation of cytotoxic effectors into memory T lymphocytes.

Opferman JT, Ober BT, Ashton-Rickardt PG.

Science. 1999 Mar 12;283(5408):1745-8.

39.

Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules.

Markiewicz MA, Girao C, Opferman JT, Sun J, Hu Q, Agulnik AA, Bishop CE, Thompson CB, Ashton-Rickardt PG.

Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3065-70.

40.

Limits to the differential avidity model of T cell selection in the thymus.

Girao C, Hu Q, Sun J, Ashton-Rickardt PG.

J Immunol. 1997 Nov 1;159(9):4205-11.

PMID:
9379014
41.

Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes.

Hu Q, Bazemore Walker CR, Girao C, Opferman JT, Sun J, Shabanowitz J, Hunt DF, Ashton-Rickardt PG.

Immunity. 1997 Aug;7(2):221-31.

42.
43.

Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.

Ljunggren HG, Van Kaer L, Ashton-Rickardt PG, Tonegawa S, Ploegh HL.

Eur J Immunol. 1995 Jan;25(1):174-8.

PMID:
7843229
44.

Altered peptidase and viral-specific T cell response in LMP2 mutant mice.

Van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, Tonegawa S.

Immunity. 1994 Oct;1(7):533-41.

PMID:
7600282
45.

A differential-avidity model for T-cell selection.

Ashton-Rickardt PG, Tonegawa S.

Immunol Today. 1994 Aug;15(8):362-6. Review.

PMID:
7916949
46.

Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.

Aldrich CJ, Ljunggren HG, Van Kaer L, Ashton-Rickardt PG, Tonegawa S, Forman J.

Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6525-8.

47.

Evidence for a differential avidity model of T cell selection in the thymus.

Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Zinkernagel RM, Tonegawa S.

Cell. 1994 Feb 25;76(4):651-63.

PMID:
8124708
48.

Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.

Schumacher TN, Kantesaria DV, Heemels MT, Ashton-Rickardt PG, Shepherd JC, Fruh K, Yang Y, Peterson PA, Tonegawa S, Ploegh HL.

J Exp Med. 1994 Feb 1;179(2):533-40.

49.

Repertoire-determining role of peptide in the positive selection of CD8+ T cells.

Ashton-Rickardt PG, Van Kaer L, Schumacher TN, Ploegh HL, Tonegawa S.

Immunol Rev. 1993 Oct;135:157-82. Review. No abstract available.

PMID:
8282312
50.

The role of peptide in the positive selection of CD8+ T cells in the thymus.

Ashton-Rickardt PG.

Thymus. 1993 Sep;22(2):111-5. Review.

PMID:
8209397

Supplemental Content

Loading ...
Support Center